Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy

NCT00694382 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

3212

Enrollment

INDUSTRY

Sponsor class

Conditions

Venous Thromboembolism
Cancer

Interventions

DRUG: Semuloparin sodium
DRUG: Placebo (for semuloparin)

Sponsor

Sanofi